Humulin Nph (Insulin Human (Rdna))

Humulin Nph is indicated for the long‑acting insulin needs of patients with diabetes.

• Type 1 diabetes mellitus (adult and pediatric) requiring basal insulin
• Type 2 diabetes mellitus when basal insulin is required
• Adjunct to mealtime insulin in mixed insulin regimens
• Use in patients needing stable overnight basal insulin coverage
• May be employed when oral antidiabetic agents are insufficient

• Humulin Nph provides a prolonged release of recombinant human insulin after subcutaneous injection. The insulin molecules bind to insulin receptors on muscle, adipose and hepatic cells, activating the receptor tyrosine kinase pathway. This stimulates translocation of GLUT‑4 transporters, enhancing glucose uptake, and suppresses hepatic gluconeogenesis, thereby lowering plasma glucose concentrations. The NPH formulation contains protamine, which delays absorption and extends the duration of action.

Adverse reactions reported with Humulin Nph vary in frequency and severity.

Common

• Hypoglycemia (low blood glucose)
• Injection site reactions such as redness, swelling or itching
• Lipodystrophy at the injection site
• Weight gain

Serious

• Severe hypoglycemia with neuroglycopenic symptoms
• Allergic reactions including urticaria, angioedema or anaphylaxis
• Hypersensitivity leading to bronchospasm
• Edema or heart failure exacerbation

When prescribing or using Humulin Nph, several precautions should be considered to ensure safe therapy.

• Adjust dose during illness, fasting, or changes in physical activity
• Monitor blood glucose regularly to avoid hypoglycemia
• Use caution in patients with renal or hepatic impairment
• Review pregnancy and lactation status, as safety data are limited
• Assess for history of allergic reactions to insulin or protamine
• Consider cardiovascular status in patients prone to fluid retention
• Avoid use in patients with known hypersensitivity to the product

Humulin Nph may interact with other medicines, affecting glucose control or insulin action.

Avoid

• Concurrent use of other rapid‑acting insulins without dose adjustment
• Beta‑blockers that mask hypoglycemia symptoms
• MAO‑inhibitors that can potentiate insulin effects
• High‑dose corticosteroids that increase insulin resistance
• Alcohol excess that predisposes to hypoglycemia

Use with caution

• Oral antidiabetic agents (e.g., sulfonylureas, meglitinides)
• Thiazide diuretics that may raise blood glucose
• ACE inhibitors or ARBs in patients with renal disease
• Lipid‑lowering agents such as fibrates
• Certain antibiotics (e.g., fluoroquinolones) that may affect glucose metabolism